Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0000950170-22-013034
Filing Date
2022-07-26
Accepted
2022-07-26 07:36:21
Documents
10
Period of Report
2022-07-26

Document Format Files

Seq Description Document Type Size
1 6-K vrax_6k_no_xbrl.htm 6-K 45538
2 EX-1.1 vrax-ex1_1.htm EX-1.1 408546
3 EX-4.1 vrax-ex4_1.htm EX-4.1 213393
4 EX-14.1 vrax-ex14_1.htm EX-14.1 202991
5 EX-99.1 vrax-ex99_1.htm EX-99.1 91010
6 EX-99.2 vrax-ex99_2.htm EX-99.2 41647
7 EX-99.3 vrax-ex99_3.htm EX-99.3 42620
8 EX-99.4 vrax-ex99_4.htm EX-99.4 189739
9 EX-99.5 vrax-ex99_5.htm EX-99.5 17302
10 EX-99.6 vrax-ex99_6.htm EX-99.6 19019
  Complete submission text file 0000950170-22-013034.txt   1272840
Mailing Address 30 BROADWICK STREET LONDON X0 W1F 8LX
Business Address 30 BROADWICK STREET LONDON X0 W1F 8LX 44 020 7788 7414
Virax Biolabs Group Ltd (Filer) CIK: 0001885827 (see all company filings)

EIN.: 000000000
Type: 6-K | Act: 34 | File No.: 001-41440 | Film No.: 221104918
SIC: 2835 In Vitro & In Vivo Diagnostic Substances